You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 159 No. 9, September 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correction
 This Article
 •PDF of this Correction
 •Original article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Errors in Text in: Continuity of Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder

Arch Pediatr Adolesc Med. 2005;159:875.

Errors in Text. In the article "Continuity of Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder" by Marcus et al published in the June issue of the ARCHIVES (2005;159:572-578), the sample sizes for both Ritalin LA and Metadate CD were inadvertently reversed in the "Selection of Study Cohorts" subsection of the "Methods" section on page 573. The correct numbers are Ritalin LA (n = 299) and Metadate CD (n = 287). The first sentence of the "Background Characteristics" subsection of the "Results" section on page 574 should read "Approximately 7 (70.1%) in 10 study patients were initially prescribed IR-MPH formulations." Also, the mean durations of treatment and associated confidence intervals (CIs) for Metadate CD and Ritalin LA were inadvertently reversed in the "ER-MPH Formulations" subsection of the "Results" section on page 575. The correct numbers are Ritalin LA, 101.1 days (95% CI, 91.2-111.0 days) and Metadate CD, 113.0 days (95% CI, 100.9-125.1 days).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.